← Ashland Global overview

Ashland Global vs Wanhua Chemical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ashland Global Holdings Inc (ASH)

Q3 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

August 2026
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Latest
▲3

Ashland's sale process advances as buyback and new product offset weak additives

  • Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.

    The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.

  • New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.

    The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.

  • New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.

    This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.

  • Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.

    This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.

Wanhua Chemical Group Co Ltd (600309.CG)

Q3 2026
▲3

Wanhua's profit surges on price hikes and tight MDI supply

  • Wanhua leads global MDI/TDI price hikes Wanhua and rivals Huntsman and BASF raised MDI and TDI prices by $200-300 per tonne, driven by higher costs and plant maintenance. As the world's largest MDI producer, Wanhua benefits directly from higher prices, lifting its revenue and profit.

    This is the core pricing driver behind Wanhua's earnings surge and stock appeal.

  • First-half profit jumps 64%, dividend announced Wanhua reported first-half revenue up 31% to 119.3 billion yuan and net profit up 64% to 10.06 billion yuan, with a 2.5 billion yuan dividend. Strong results confirm the upcycle and reward shareholders, supporting the stock price.

    Earnings and dividend are the clearest fundamental proof of the company's health.

  • Global MDI supply stays tight through 2028 Analysts expect a global MDI supply-demand gap of about 220,000 tonnes from 2026 to 2028, with capacity shifting to China where Wanhua has a cost advantage. Tight supply supports higher prices and margins for Wanhua.

    This structural supply gap underpins the positive long-term outlook for Wanhua's main product.

  • Maintenance shutdowns and restarts balance supply Wanhua's Yantai MDI plant shut for 45 days from August 10 and restarted by September 29, while its Fujian and Hungarian units also resumed. These routine outages temporarily tighten supply but restore volumes, keeping overall supply stable.

    Plant maintenance and restarts affect near-term supply but are routine and largely neutral for the big picture.

August 2026
▲3

Wanhua's profit surges on price hikes and tight MDI supply

  • Wanhua leads global MDI/TDI price hikes Wanhua and rivals Huntsman and BASF raised MDI and TDI prices by $200-300 per tonne, driven by higher costs and plant maintenance. As the world's largest MDI producer, Wanhua benefits directly from higher prices, lifting its revenue and profit.

    This is the core pricing driver behind Wanhua's earnings surge and stock appeal.

  • First-half profit jumps 64%, dividend announced Wanhua reported first-half revenue up 31% to 119.3 billion yuan and net profit up 64% to 10.06 billion yuan, with a 2.5 billion yuan dividend. Strong results confirm the upcycle and reward shareholders, supporting the stock price.

    Earnings and dividend are the clearest fundamental proof of the company's health.

  • Global MDI supply stays tight through 2028 Analysts expect a global MDI supply-demand gap of about 220,000 tonnes from 2026 to 2028, with capacity shifting to China where Wanhua has a cost advantage. Tight supply supports higher prices and margins for Wanhua.

    This structural supply gap underpins the positive long-term outlook for Wanhua's main product.

  • Maintenance shutdowns and restarts balance supply Wanhua's Yantai MDI plant shut for 45 days from August 10 and restarted by September 29, while its Fujian and Hungarian units also resumed. These routine outages temporarily tighten supply but restore volumes, keeping overall supply stable.

    Plant maintenance and restarts affect near-term supply but are routine and largely neutral for the big picture.

Latest
▲3

Wanhua's profit surges on price hikes and tight MDI supply

  • Wanhua leads global MDI/TDI price hikes Wanhua and rivals Huntsman and BASF raised MDI and TDI prices by $200-300 per tonne, driven by higher costs and plant maintenance. As the world's largest MDI producer, Wanhua benefits directly from higher prices, lifting its revenue and profit.

    This is the core pricing driver behind Wanhua's earnings surge and stock appeal.

  • First-half profit jumps 64%, dividend announced Wanhua reported first-half revenue up 31% to 119.3 billion yuan and net profit up 64% to 10.06 billion yuan, with a 2.5 billion yuan dividend. Strong results confirm the upcycle and reward shareholders, supporting the stock price.

    Earnings and dividend are the clearest fundamental proof of the company's health.

  • Global MDI supply stays tight through 2028 Analysts expect a global MDI supply-demand gap of about 220,000 tonnes from 2026 to 2028, with capacity shifting to China where Wanhua has a cost advantage. Tight supply supports higher prices and margins for Wanhua.

    This structural supply gap underpins the positive long-term outlook for Wanhua's main product.

  • Maintenance shutdowns and restarts balance supply Wanhua's Yantai MDI plant shut for 45 days from August 10 and restarted by September 29, while its Fujian and Hungarian units also resumed. These routine outages temporarily tighten supply but restore volumes, keeping overall supply stable.

    Plant maintenance and restarts affect near-term supply but are routine and largely neutral for the big picture.